Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KALA 
Kala Pharmaceuticals Inc (KALA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: KALA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.5
1 Year Target Price $1.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.92% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.59M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) 2 | Beta -2.49 | 52 Weeks Range 0.61 - 20.60 | Updated Date 12/4/2025 |
52 Weeks Range 0.61 - 20.60 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -65.81% | Return on Equity (TTM) -708.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 16440995 | Price to Sales(TTM) 1.16 |
Enterprise Value 16440995 | Price to Sales(TTM) 1.16 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA -0.16 | Shares Outstanding 8209725 | Shares Floating 8153735 |
Shares Outstanding 8209725 | Shares Floating 8153735 | ||
Percent Insiders 1.86 | Percent Institutions 17.29 |
Upturn AI SWOT
Kala Pharmaceuticals Inc
Company Overview
History and Background
Kala Pharmaceuticals, Inc. was founded in 2009. It focused on developing and commercializing innovative therapies for eye diseases. Initially, it focused on a proprietary mucus-penetrating particle (MPP) technology to improve drug delivery to the eye. Kala experienced financial challenges and was delisted in 2023.
Core Business Areas
- Eyecare Pharmaceuticals: Developed and commercialized prescription ophthalmic products using its MPP technology, primarily for inflammatory and allergic eye conditions.
Leadership and Structure
Information on specific current leadership structure is limited due to the company's financial difficulties and delisting. In the past, it had a CEO, CFO, and other key management positions overseeing R&D, commercial operations, and finance. Organisational structure was typical of a publicly traded pharmaceutical company.
Top Products and Market Share
Key Offerings
- Lotemax SM: A corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. Lotemax SM faced competition from other topical steroids and nonsteroidal anti-inflammatory drugs (NSAIDs). Market share data is difficult to obtain due to the company's financial challenges and subsequent delisting, and is fragmented across all ocular steroids.
- Inveltys: A corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. It competed with other topical steroids like Durezol, and NSAIDs. Again, market share data is not easily available and is fragmented
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is driven by an aging population, increasing prevalence of eye diseases, and technological advancements in drug delivery and treatment options.
Positioning
Kala Pharmaceuticals aimed to differentiate itself through its MPP technology, designed to improve drug penetration and efficacy in the eye. However, its financial difficulties hampered its ability to effectively compete with larger, more established players.
Total Addressable Market (TAM)
The global ophthalmic drugs market is significant (estimated in the tens of billions of dollars). Kala's positioning within this TAM was limited by its product portfolio and financial constraints.
Upturn SWOT Analysis
Strengths
- MPP technology for enhanced drug delivery
- Approved ophthalmic products (Lotemax SM, Inveltys)
- Experienced R&D team focused on ocular diseases
Weaknesses
- Financial instability and delisting
- Limited commercial reach compared to larger competitors
- Reliance on a small number of key products
- High debt burden
Opportunities
- Potential for partnerships or acquisitions
- Development of new formulations using MPP technology
- Expansion into new ophthalmic indications
Threats
- Competition from established pharmaceutical companies
- Generic erosion of existing products
- Regulatory hurdles and pricing pressures
- Failure to secure additional funding
Competitors and Market Share
Key Competitors
- AGN (AbbVie, Allergan)
- SNY (Sanofi)
- PFE (Pfizer)
- NOVN (Novartis)
Competitive Landscape
Kala Pharmaceuticals faced significant disadvantages compared to its larger competitors due to its limited resources, smaller product portfolio, and financial instability.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was inconsistent, with periods of initial product launch success followed by financial struggles.
Future Projections: Future projections are highly uncertain due to the company's financial situation. Re-emergence as a viable company is speculative.
Recent Initiatives: Recent initiatives focused on restructuring and cost-cutting measures to preserve cash.
Summary
Kala Pharmaceuticals struggled due to financial issues despite its MPP technology. Its promising products were overshadowed by debt and competition. The company needs to undergo significant restructuring or acquisition to survive. Future prospects remain highly uncertain, given its current financial state and market conditions. Its strengths in technology were insufficient to overcome financial weaknesses.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (historical)
- Industry reports
- Market research reports
Disclaimers:
The information provided is based on publicly available data and analyst estimates. The analysis is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kala Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Arlington, MA, United States | ||
IPO Launch date 2017-07-20 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.kalarx.com |
Full time employees 38 | Website https://www.kalarx.com | ||
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.